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Abstract. – OBJECTIVE: Familial hypertrophic 
cardiomyopathy (HCM) is the most common ge-
netic cardiac disease. While sarcomeric gene 
mutations explain many HCM cases, the genet-
ic basis of about half of HCM cases remains elu-
sive. Here we aimed to identify the gene causing 
HCM in a non-consanguineous Saudi Arabian 
family with affected family members and a his-
tory of sudden death. The impact of the identi-
fied mutation on protein structure and potential 
drug targets were evaluated in silico. 
MATERIALS AND METHODS: Triplets (two 
HCM subjects and one patent ductus arterio-
sus (PDA) case) and unaffected parents were 
screened by targeted next-generation sequenc-
ing (NGS) for 181 candidate cardiomyopathy 
genes. In silico structural and functional anal-
yses, including protein modeling, structure 
prediction, drug screening, drug binding, and 
dynamic simulations were performed to explore 
the potential pathogenicity of the variant and to 
identify candidate drugs. 
RESULTS: A homozygous missense mutation 
in exon 1 of TMP1 (assembly GRCh37-chr15: 
63340781; G>A) was identified in the triplets 
[two HCM and one patent ductus arteriosus 
(PDA)] that substituted glycine for arginine at 
codon 3 (p.Gly3Arg). The parents were heterozy-
gous for the variant. The mutation was predicted 
to cause a significant and deleterious change in 
the TPM1 protein structure that slightly affected 
drug binding, stability, and conformation. In ad-
dition, we identified several putative TPM1-tar-
geting drugs through structure-based in silico 
screening.
CONCLUSIONS: TPM1 mutations are a com-
mon cause of HCM and other congenital heart 
defects. To date, TPM1 has not been associated 
with isolated PDA; to our knowledge, this is the 
first report of the homozygous missense varia-
tion p.Gly3Arg in TPM1 associated with familial 
autosomal recessive pediatric HCM and PDA. 
The identified candidate TPM1 inhibitors warrant 
further prospective investigation.
Key Words:
Pediatric familial hypertrophic cardiomyopathy, Tar-
geted Gene sequencing, TPM1, Saudi Arabia, Con-
sanguinity, Molecular docking, Molecular dynamics.
Introduction
Hypertrophic cardiomyopathy (HCM) is an 
inherited cardiac disease characterized by left 
ventricular hypertrophy that is associated with 
a number of potential clinical outcomes, includ-
ing impaired diastolic function, heart failure, 
and sudden cardiac death (SCD). HCM is rare 
in the pediatric population but affects over 1 in 
500 of the general adult population1. It is also 
one of the most common causes of SCD in young 
athletes2,3.
HCM has mainly been considered an auto-
somal dominant disease, although some cases 
can be explained by de novo mutations and, less 
European Review for Medical and Pharmacological Sciences 2020; 24: 7732-7744
S.J. CARLUS1, I.S. ALMUZAINI2, M. KARTHIKEYAN3, L. LOGANATHAN3, 
G.S. AL-HARBI1, F.H. CARLUS4, A.H. AL-MAZROEA1, M.M. MORSY5, 
H.M. ABO-HADED1,6, A.M. ABDALLAH7, K.M. AL-HARBI1
1Cardiogenetics Unit, Pediatrics Department, College of Medicine, Taibah University, Al-Madinah, 
 Kingdom of Saudi Arabia
2Department of Pediatric Cardiology, Al-Madinah Maternity and Children Hospital (MMCH), 
 Al-Madinah, Kingdom of Saudi Arabia
3Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India
4Department of Zoology, Pachaiyappa’s College Chennai-30, India
5Madina Cardiac Center, Al-Madinah, Kingdom of Saudi Arabia
6Pediatric Cardiology Unit, Department of Pediatrics, Faculty of Medicine, Mansoura University, Egypt
7College of Health Sciences, QU Health, Qatar University, Doha, Qatar
Corresponding Author: S. Justin Carlus, Ph.D; e-mail: justincarlus@gmail.com
A novel homozygous TPM1 
mutation in familial pediatric hypertrophic
cardiomyopathy and in silico screening
of potential targeting drugs
TPM1 mutation in pediatric familial dilated cardiomyopathy
7733
commonly, autosomal recessive inheritance. 
Pathogenic mutations are usually detected in 
eight genes encoding sarcomeric proteins, which 
generate the molecular force of myocyte contrac-
tion, with 50% of mutations occurring in cardiac 
myosin-binding protein C (MYBPC3) and beta 
myosin heavy chain (MYH7). Other HCM genes 
include cardiac troponin T2 (TNNT2), cardiac 
troponin I (TNNI3), alpha tropomyosin (TPM1), 
myosin regulatory light chain (MYL2), myosin 
essential light chain (MYL3), and cardiac al-
pha actin (ACTC1), which harbor a much lower 
frequency of pathogenic variants (1-5% each)4. 
Overall, mutations in over 70 genes have been 
reported to cause HCM, accounting for 50-60% 
of affected individuals but leaving the remainder 
without a known genetic basis5. TPM1 is a high-
ly conserved actin-binding protein belonging to 
the tropomyosin family. The main function of 
the protein is as part of the troponin complex, 
regulating the calcium-dependent interaction 
of actin and myosin during muscle contraction. 
Specifically, targeting the myofilament mole-
cules involved in muscle contraction could pos-
itively regulate Ca2+-based signaling pathways, 
so TPM1 could be a drug target for the preven-
tion and treatment of HCM6.
Our surveys of the registry of a pediatric 
cardiology clinic at the Madinah Maternity and 
Children Hospital (MMCH), Al-Madinah, Saudi 
Arabia revealed a very high prevalence of cardio-
myopathy in the pediatric heart patient popula-
tion7. Saudi Arabia has one of the highest rates of 
consanguinity in the world, as marriages between 
first cousins and close relatives are widely accept-
ed and frequently occur8. Consanguinity may be 
a risk factor for some congenital abnormalities9. 
Unfortunately, few studies have been conducted 
on Saudi Arabian cardiomyopathy patients, and 
the disease remains poorly understood in this 
population.
Here we aimed to identify novel mutation(s) 
and gene(s) responsible for familial HCM us-
ing targeted next-generation sequencing (NGS) 
technology in a Saudi Arabian family with af-
fected family members. In doing so, we identi-
fied a novel homozygous missense mutation in 
TMP1 in affected individuals. To provide func-
tional insights, in silico analysis was used to pre-
dict the deleterious effect of the mutation and to 
understand its impact on protein structure and 
drug binding. Potential TPM1 inhibitors were 




This study was conducted fully in accordance 
with the ethical standards of the Taibah Universi-
ty Ethical Research Committee, the Ethical Re-
view Board of Madinah Maternity and Children 
Hospital (MMCH), and with the 1964 Helsinki 
Declaration and its later amendments or compa-
rable ethical standards.
Study Participants and Clinical 
Evaluation
Peripheral blood samples were collected from 
five individuals: triplets [two HCM subjects and 
one patent ductus arteriosus (PDA) case] and 
unaffected normal parents from a non-consan-
guineous Saudi Arabian family attending the 
Department of Pediatric Cardiology, MMCH. 
The parents provided written informed consent 
for study participation. HCM was diagnosed ac-
cording to published guidelines10,11 using the fam-
ily history, physical and clinical examination, 
electrocardiography (ECG), chest x-rays, and 
2D-echocardiography. Doppler echocardiography 
was performed using a Hewlett-Packard 1500 or 
5500 echocardiographic system. In adults, HCM 
is usually defined by a maximal LV wall thick-
ness ≥15 mm on echocardiography, with a wall 
thickness of 13 to 14 mm considered borderline, 
particularly in the presence of other compelling 
information (e.g., family history of HCM). In 
children, an increased LV wall thickness is de-
fined as a wall thickness ≥2 standard deviations 
above the mean (z-score ≥2) for age, sex, or body 
size. In familial cases, the diagnosis can be made 
using echocardiographic criteria as above and/
or one of the following ECG abnormalities: LV 
hypertrophy (Romhilt-Estes score >4); Q-waves 
(duration >0.04 s and/or a depth >1/4 of ensuring 
R wave in at least two leads); or marked repolar-
ization abnormalities (T wave inversion in at least 
two leads).
Cardiomyopathy Gene Panel, Targeted 
Gene Sequencing, and Bioinformatics 
Analysis
Targeted sequencing of 181 cardiomyopathy 
disease genes was performed on the five samples. 
The development of an in-house custom gene 
panel covering 181 cardiomyopathy genes, DNA 
extraction, targeted sequencing, and bioinformat-
ics analysis are described in our previous publi-
cation7.
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Validation by Sanger Sequencing
Sanger sequencing was performed to confirm 
the presence of the variant. Primer sequences 
were designed using Primer3. The primer pairs 
used for PCR were forward: 5’-ACTTCCG-
GACTGCTCCT-3’ and reverse: 5’-GTGATGG-
GTGTATCCCTTACG-3’. The amplicons were 
directly sequenced using BigDye chain termi-
nation chemistry on an ABI 3730 DNA analyzer 
(Applied Biosystems, Foster City, CA, USA).
Sequence and Structure Data Collection
The TPM1 gene was targeted to assess the 
identified variant’s role on the protein structure. 
A full-length protein crystal structure was not 
available; therefore, a molecular modeling ap-
proach was used to build a new tertiary structure. 
The protein sequence was collected from the Uni-
ProtKB database (P09493) and the tertiary struc-
ture predicted using several computational tools, 
including SWISS-MODEL, Robetta, and I-TASS-
ER12. After typical structure validations, a signif-
icant model was selected for further analysis. All 
in silico analyses were carried out on the CentOS 
v7.0 Linux platform with an Intel® Core™ i7-4770 
CPU@3.40 GHz processor using the Schröding-
er platform (Schrödinger, New York, NY, USA; 
2018-4 package)13.
Sequence Alignment and Secondary 
Structure Prediction
The protein sequence was used for sequence 
alignment using Geneious Pro software (Auck-
land, New Zealand). The mutant TPM1 protein 
sequences were prepared by manually editing the 
FASTA file. Both wild and mutant-type protein 
sequences were aligned by MAFFT alignment 
v.7.017 with the Blosum62 matrix14. The aligned 
sequence was further used for secondary struc-
ture prediction, with the results visualized to find 
secondary structure differences, namely a loss of 
loops and addition of a helix around the mutation 
site (Figure 1).
Protein Structure Modeling
The best TPM1 protein structure was predict-
ed using Robetta15, the mutation lying in the third 
residue and therefore not predicted to significant-
ly impact the structure. Molecular modeling did 
not reveal any major difference in the early sec-
tion of the protein (Figure 2A). Hence, an ab in-
itio modeling protocol was utilized to model the 
TPM1 protein.
Molecular Dynamics Simulation
The TPM1 protein was subjected to molecu-
lar dynamics simulation using Desmond v2.3, 
(Schrödinger)16, an approach that helps to identify 
structural changes in wildtype and mutant pro-
teins. The system was also utilized to analyze the 
root mean square deviation (RMSD) and the root 
mean square fluctuation (RMSF). The wildtype 
and mutant protein structures were processed 
separately for molecular dynamics simulation to 
observe the effect of the mutation on the protein 
structure, hypothesizing that there would be no 
significant difference between the wild and mu-
tant-type protein structure such that these pro-
teins may be considered as drug targets due to 
their conserved nature. The protein structure was 
considered as a system with ions added in the sin-
gle point charge (SPC) solvent model. An orthor-
hombic box was placed around the molecule to 
add solvent and ions. Approximately 22 sodium 
ions at 0.15 M concentration were added to neu-
tralize the whole system. The NVT ensemble was 
set with the thermostat using the Nose-Hoover 
chain algorithm at 300 K and 1 bar pressure at 
Figure 1. Secondary structure prediction of wild type and mutated TPM1 protein.
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1.0 ps and 2.0 ps relaxation time, respectively. Fi-
nally, the whole system was submitted for a 20 
ns simulation. After completion of the simulation, 
the whole trajectory file was utilized to analyze 
the RMSD and RMSF with respect to the initial 
structure.
Molecular Docking Studies
The predicted tertiary structure of TPM1 was 
used for molecular docking studies using a virtual 
screening workflow. To identify potential TPM1 
inhibitors, we selected a natural small molecule 
database, Life Chemicals17. The 2D structures of 
the screened compounds were retrieved from the 
Life Chemicals web server. The potential activities 
of the screening compounds were compared with 
known drugs listed in the Human Gene Database18.
Protein Preparation
The predicted tertiary structure of TPM1 was 
prepared using the Protein Preparation Wizard in 
Maestro (Schrödinger). In the preprocessing step, 
hydrogens, bond length, missing side chains, and 
loops were added. Hydrogen bonds were opti-
mized, and the final structure was minimized. In 
order to obtain a proper structure, the obtained 
protein was used for restrained energy minimi-
zation with an RMSD cutoff of 0.3 nm using 
OPLS3e19. The minimized protein structure of 
TPM1 was then used in downstream analyses.
Active Site Prediction And Grid 
Generation
The refined protein structure was used 
for active site prediction using Sitemap v4.9 
(Schrödinger). The active site of the target pro-
tein consists of only a single coiled-coil domain. 
A hydrophobic rich region is essential for molec-
ular docking analysis. Therefore, we focused on 
identifying more hydrophobic sites and hydrogen 
bond acceptor-rich and donor-rich sites, which 
better define the active site of the protein. Of the 
five top ranked sites in the protein, the best site 
was selected based on the site score and the area 
coverage (Figure 2B). The identified best site was 
used to define the grid box around the active site 
of the protein using the Receptor Grid Generation 
Panel in Glide (Schrödinger).
Ligand Preparation
The database compounds and standard drug 
molecules were used for ligand preparation. All 
2D structure files were imported for conversion 
to 3D structures with generated conformers20. 
The ligands were prepared following the standard 
protocol. Approximately 288,651 compounds 
were used for 3D conversion and minimization of 
chemical compounds using Ligprep in Maestro 
(Schrödinger). Conformers were generated using 
a rapid torsion angle search approach followed 
by minimization of each generated structure us-
ing the OPLS-3e force field, with 30 implicit GB/
SA solvent models21. Thirty-two conformers were 
generated for all the compounds based on the ro-
tatable bonds present in the ligand molecules.
Virtual Screening Workflow
A structure-based virtual screening workflow 
was used to screen the large chemical compound da-
tabase to identify possible lead molecules. The com-
pounds in the Life Chemicals database (288,651) 
were screened using the active site of the TPM1 
complex using the Glide-VSW module. The virtual 
screening workflow is a well-defined protocol that 
filters chemical compounds by screening and dock-
ing. Initially, the QikProp filter was applied with 
Lipinski’s Rule, followed by the high-throughput 
virtual screening (HTVS), standard precision (SP), 
Figure 2. A, Modeled tertiary structure of the TPM1 protein with labeled mutation site. B, The predicted active site consists 
of hydrophobic surfaces and hydrogen bond acceptor and donor-rich regions in the TPM1 protein.
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and finally extra precision (XP) docking programs 
to screen potential ligands. Lipinski’s rule in Qik-
Prop helps to eliminate non-drug-like compounds22. 
Glide HTVS and SP docking use a series of hierar-
chical filters to find the best possible ligand-binding 
locations in the defined receptor grid space. Further, 
the poses generated by Glide SP were again refined 
by Glide XP23. At each stage of HTVS, SP, and 
XP, the top 10% compounds were retained for the 
next stage24. In this way, database compounds were 
screened individually with the predicted protein 
structure and the results were scrutinized to find po-
tential inhibitors. Top-hit compounds were ranked 
according to the Glide XP score, Glide energy, and 
interacting protein residues with the compound. The 
Glide XP score represents the total g-score or final 
score to identify the best ligand. Best pose identi-
fication was calculated through the non-bonded in-
teractions, while the Glide energy was a modified 
Coulomb-van der Waals interaction energy score. 
The Glide energy is useful for comparing the bind-
ing affinities of different ligands. The top ten ligands 
from the Life Chemicals database were further used 
in downstream analyses.
Binding Energy Calculation
Binding energy calculations were conduct-
ed for the top ten protein-ligand complexes and 
with standard drug molecules using the Prime/
MM-GBSA approach25. MM-GBSA is a post 
scoring approach that helps to evaluate molecu-
lar docking and validate the accuracy of differ-
ent compounds. This method is very helpful for 
predicting the binding energy of different sets of 
ligand poses to the receptor. The following equa-
tions were used to calculate the binding energy:
ΔGbind = ΔE + ΔGsolv + ΔGSA……….(1)
ΔE = Ecomplex – Eprotein – Eligand…….(2)
where Ecomplex, Eprotein, and Eligand are 
the minimized energies of the protein-inhibi-
tor complex, protein, and inhibitor, respective-
ly; ΔGsolv is the generalized Born electrostatic 
solvation energy of the complex; and ΔGSA is a 
non-polar contribution to the solvation energy due 
to the surface area26.
Absorption, Distribution, Metabolism,
Excretion (ADME) Prediction
Absorption, distribution, metabolism, excre-
tion (ADME) is an essential approach for ana-
lyzing the physicochemical properties of drugs. 
Early data collection on ADME27 properties pro-
vides useful insights into drug formulations and 
clinical suitability. The identified best lead com-
pounds were studied for their ADME properties 
using the QikProp module (Schrödinger). The 
required principle and physiochemical properties 
of drug compounds were predicted from the de-
fined dataset and the acceptability of the known 
and screened compounds was evaluated based on 
Lipinski’s rule of five22.
Results
Clinical Assessment of the HCM Family
The triplets were born of non-consanguineous 
Saudi parents. The father was 36 years old and 
the mother was 32 years old. The father had no 
significant medical history and the mother had 
type 1 diabetes mellitus. Both parents had nor-
mal echocardiograms. There was a family history 
of sudden cardiac death on the mother’s side; two 
cousins died aged 20 and 27 years from HCM. 
The family pedigree was highly suggestive of a 
recessive pattern of inheritance (Figure 3A). The 
triplets were six years old and born preterm (31 
weeks’ gestation).
At birth, subject 1 weighed 1.5 kg and was ad-
mitted to the neonatal intensive care unit (NICU) 
and ventilated due to low birth weight, respiratory 
distress, and need for respiratory support because 
of frequent apnea. Echocardiography revealed left 
ventricular hypertrophy, no left ventricular outflow 
tract (LVOT) obstruction, and normal left ventric-
ular (LV) systolic functions. The primary diagno-
sis was HCM with disease onset since birth. Other 
clinical symptoms were seizures, brain hemor-
rhage, cerebral palsy, and bronchial asthma.
Subject 2 weighed 1.3 kg at birth and was 
admitted to the NICU and ventilated due to low 
birth weight, respiratory distress, and for respira-
tory support because of frequent apnea. Echocar-
diography revealed a tiny patent ductus arteriosus 
(PDA) but no manifestation of HCM. A brain CT 
was normal. Other clinical symptoms were bron-
chial asthma and diabetic ketoacidosis, which de-
veloped at three years of age.
Subject 3 weighed 900 g at birth and was ad-
mitted to the NICU and ventilated due to low 
birth weight, respiratory distress, and need for 
respiratory support because of frequent apnea. 
Echocardiography revealed mild LV septal hy-
pertrophy but without LVOT obstruction. Brain 
CT was normal.
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Genetic Analysis and Systematic 
Prioritization of Candidate Variants
Targeted sequencing of 181 cardiomyopathy 
disease genes was performed on the triplets (two 
HCM subjects and one PDA case) and their par-
ents’ samples. A mean of 0.6 Gb of sequence was 
generated per individual, of which 94.2% of bases 
had ≥Q30 quality and over 98% of reads aligned 
to the human genome. Bioinformatics analysis de-
tected a homozygous missense mutation in exon 
1 of the TMP1 gene (on assembly GRCh37-chr15: 
63340781; G>A; ENSG00000140416; rs397516490) 
in all triplets (HCM subjects and one PDA case), 
which resulted in a glycine for arginine substitu-
tion at codon 3 (p.Gly3Arg) (Figure 3B). The vari-
ant was heterozygous in the parental samples.
This variant has not been described in the ExAC 
Aggregation Consortium (ExAC) database (>60,000 
samples), the 1000 Genomes (1KG) database (2,500 
samples), the Exome Sequencing Project (ESP) da-
tabase (6,500 samples), or in the Atlas of Cardiac 
Genetic Variation (https://www.cardiodb.org/acgv/
acgv_variant.php). However, while the variant has 
been reported in ClinVar (RCV000036633.3), its 
pathogenicity has not been clinically demonstrated. 
The in silico variant was predicted to be “probably 
Figure 3. A, Family pedigree, with proband indicated with an arrow. Males are depicted as squares, females as circles, 
unknown gender depicted as diamonds, and deceased individuals with a diagonal line. Blue and brown shading represent 
individuals who are clinically affected triplets (two HCM subjects and one PDA case), while no shading indicates unaffected 
individuals. Het indicates a heterozygous TPM1 p.Gly3Arg mutation and Hom indicates the homozygous TPM1 p.Gly3Arg 
mutation. B, Homozygous missense mutation in exon 1 of TPM1 (chr15: 63340781; G>A) resulting in the substitution of gly-
cine for arginine at codon 3 (p.Gly3Arg) in affected HCM and PDA subjects. The mutation was present in the heterozygous 
state in unaffected parents. 
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damaging” by PolyPhen-2, “damaging” by MetaLR, 
“damaging” by SIFT (low confidence), “disease 
causing” by MutationTaster2, and “pathogenic” by 
REVEL28.
Protein Structure Prediction
The tertiary protein structure of TPM1 was 
modeled on the Robetta server. The domain, pre-
dicted by the Ginzu domain prediction algorithm 
in Robetta, consisted of 1-245 amino acids with a 
confidence score of 0.997. The domain has a pre-
dicted coiled-coil structure with two polypeptide 
chains. The predicted structure was validated with 
the Procheck tool29, and the Ramachandran plot 
showed that 99.6% of residues were in favored/
allowed regions and 0.4% were in disallowed re-
gions (Figure 4A). The amino acids located in the 
disallowed regions were optimized during energy 
minimization of the modeled protein.
Molecular Dynamics Simulation
The structural stability of the predicted model 
of TPM1 was analyzed using Desmond software. 
The molecular dynamics simulation revealed that 
the predicted model was stable and compact. A 
20 ns simulation run was used to plot RMSD and 
RMSF data generated through the trajectory files. 
The RMSD plot showed that the modeled protein 
was stable with an RMSD value of 6-5 Å. The 
mutated protein deviated little from the wild type 
protein structure (~1 Å) (Figure 4B). The RMSF 
plot helps to visualize the relative changes in res-
idue fluctuation, with a large fluctuation observed 
at the start and end residues of the protein; the 
fluctuation was higher at the end of the protein. 
The active site residues Gln 20, Arg27, Arg202, 
Phe205, Ser209, and Ser216 were considered as 
interacting residues and have a leading role in 
ligand binding. The RMSF plot clearly shows 
that fluctuation of these residues was under 3.0 
Å (Figure 4C), with the wild type protein having 
slightly higher fluctuations than the mutant-type 
structure. Finally, the molecular dynamics study 
confirmed that the structural stability and confor-
mational changes persisted throughout the simu-
lation period.
Structure-Based Virtual Drug Screening
A virtual drug screening approach can help to 
identify potential inhibitors of wildtype and mu-
tant protein structures. The refined TPM1 protein 
structure with a defined active site was used as 
the receptor to dock database compounds. 228 
compounds were identified as top hit molecules 
from virtual screening. Of these, we selected the 
top ten compounds with good Glide gscores and 
non-covalent interactions, which were then visu-
alized using both 2D (Figure 5A and B) and 3D 
(Figure 6) binding poses in the active site. Notably, 
the top five Life Chemical compounds (F0760-
0534, F1899-0458, F1691-3363, F1278-0497, and 
F2258-0953) had Glide gscores between -5.381 
and -4.677 kcal/mol with Glide energies ranging 
from -44.991 to -31.682 kcal/mol. From these re-
sults, we propose that these five small molecules 
may act as a potential TPM1 inhibitors. Further-
more, the observed binding energy of the top hit 
molecule was -58.57 to -39.30 kcal/mol, denoting 
strong binding affinity towards TPM1. Several 
hydrogen bond interactions were observed be-
tween the ligand and protein. Specifically, Arg27, 
Gln20, Ser209, and Arg202 formed hydrogen 
Figure 4. A, The Ramachandran plot values for the predicted protein structure model of TPM1. B, The RMSD of the modeled 
TPM1 protein from a 20 ns simulation. C, RMSF plot of the wild and mutant structure model of TPM1 from a 20 ns simulation.
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bonds with the ligand molecules. The 2D and 3D 
interactions clearly show the binding poses of the 
top five compounds (Figures 5 and 6).
Similar activity and binding affinity were ob-
served in the mutated protein structure. The Glide 
gscores ranged from -5.354 to -3.471 kcal/mol, 
and the Glide energy and binding energy ranged 
from -42.391 to -31.471 kcal/mol and -56.52 to 
-39.87 kcal/mol, respectively. The glide gscores 
were very similar for the top four compounds, 
but compound F2258-0953 had a very low Glide 
gscore and binding energy. Similarly, the binding 
affinities of the mutated protein were similar to 
wildtype. Therefore, the docking scores and in-
Figure 5. A, The 2D interaction pattern of the top five hit compounds. a) F0760-0534, b) F1899-0458, c) F1691-3363, d) 
F1278-0497, and e) F2258-0953. B, The 2D interaction pattern of the standard drugs with TPM1. a, c) CID-6918483; b, d) 
CID-16741.
Figure 6. A, The 3D interaction pattern and binding poses of the screened compounds and standard drugs in the TPM1 active 
site. B, The electrostatic surface of the top hit Life Chemicals compounds (green surface) in the active site of TPM1.
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teractions between compounds and wildtype and 
mutant structures were similar, suggesting that 
the Gly3Arg mutation does not significantly af-
fect drug binding and affinity towards the TPM1 
protein active site.
Evaluation of “Standard” Drugs
The “standard” drugs predicted to target 
TPM1, namely dihydroartemisinin (PubChem 
ID: 6918483), and phenethyl isothiocyanate (Pub-
Chem ID: 16741) were docked individually to 
both wildtype and mutated TPM1 proteins. These 
drugs are predicted to have activity against TPM1 
based on the evidence provided from the Human 
Genome Database and, as expected, the molecular 
docking studies showed that the standard drugs 
had good binding affinity towards the TPM1 ac-
tive site. The Glide gscores were comparatively 
lower than the compounds identified from screen-
ing (Tables I and II) at -3.169 and -2.183 kcal/
mol in wildtype and -3.300 and -2.372 kcal/mol 
in mutant proteins for dihydroartemisinin and 
phenethyl isothiocyanate, respectively. There 
were significant differences in Glide gscore, glide 
energy, binding energy, and number of interacting 
residues between the two standard drugs and top 
hit compounds. The standard drugs only formed 
three hydrogen bonds with Gln20, Arg27, and 
Arg202. Figure 6 shows the binding poses of the 
top compounds with the compounds highlighted 
inside the green surfaces and the binding site indi-
cated by electrostatic surfaces. The binding site is 
in a hydrophobic cavity with electropositive (blue) 
and electronegative regions (red).
Pharmacokinetic Properties
The ADME or pharmacokinetic properties 
of the identified compounds were estimated us-
ing QikProp. All five top hit compounds were 
within an acceptable range (shown in parenthe-
ses below) and could be identified as drug-like 
compounds. The molecular weight of the com-
pounds ranged from 344.4 to 496.4 g/mol (130 
to 725 g/mol). The log Kp is a useful assessment 
of potential compound penetration through 
skin, and the predicted skin permeability 
QPlogKp ranged from -1.629 to -5.155 (-8.0 to 
-1.0). The predicted aqueous solubility QPlogS 
was between -4.169 to -6.424 (-6.5 to 0.5), and 
the predicted perceptible Caco-2 cell permea-
bility of the compounds was 45.728 to 652.512 
nm/sec (<25 poor permeability; >500 high per-
meability). The predicted IC50 values for block-
age of HERG K+ channels were -4.0 to -6.4 (<-5 
is a “good” value). The predicted blood/brain 
partition coefficients were -2.4 to 0.8 (-3.0 to 
1.2). The percentage human oral absorption 
was predicted for the identified compounds 
using a quantitative multiple linear regression 
model. All compounds had >50% oral absorp-
tion (range 50-100%, where <25% is low and 
>80% is high) (Table III). Further, we assessed 
whether the candidate compounds violated the 
“rule of five” prediction, and they did not vio-
late any rule (mol_MW < 500, QPlogPo/w < 5, 
donorHB ≤ 5, accptHB ≤ 10). Compounds that 
satisfy the rule of five can be considered drug-
like compounds30, so these compounds could be 
potential inhibitors of TPM1.
Table I. Molecular docking results for the identified top hit and standard compounds for the wildtype protein.
Compound ID Glide  Glide ΔG bind Interacting
 gscore  energy energy residues
 (kcal/mol)  (kcal/mol) (kcal/mol)  
F0760-0534 -5.381 -44.171 -50.42 Arg27, Ser209
F1691-3363 -5.229 -41.199 -41.50 Gln20, Arg27, Arg202
F2258-0953 -5.132 -40.200 -40.05 Gln20, Arg27, Ser209
F1278-0497 -4.856 -31.682 -47.64 Arg27
F1899-0458 -4.770 -44.014 -58.57 Arg202, Phe205, Ser216
F1089-0033 -4.764 -38.405 -43.10 Phe205
F2096-0085 -4.798 -44.991 -52.91 Ser209, Lys212
F2256-0264 -4.711 -37.176 -46.26 Gln20, Arg202
F1847-0028 -4.678 -35.794 -45.18 Arg27, Ser209
F2539-0318 -4.677 -34.193 -39.30 Arg27, Arg202
PubChem_CID-6918483 -3.169 -19.030 -29.26 Gln20, Arg27
PubChem_CID-16741 -2.183 -18.207 -24.65 Arg202
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Discussion
HCM is a global disease31 and is considered 
one of the most common inherited heart disor-
ders, with an estimated prevalence of over 1 in 
5001. Identifying novel mutations and genes re-
sponsible for familial HCM is important, both for 
providing treatment and prevention strategies and 
for triggering clinical and genetic surveillance of 
family members.
Saudi Arabia has one of the highest rates of 
consanguinity in the world, as marriages between 
first cousins and close relatives are common and 
widely accepted8. There has been no decrease in 
the prevalence of consanguinity over a generation, 
with the tradition of marrying within the family 
still a preferred practice despite the awareness 
that certain genetic disorders occur at a higher 
frequency in cousin marriages32. Consanguinity 
is a risk factor for some congenital abnormalities9. 
In Al-Madinah, in Western Saudi Arabia, the 
prevalence of cardiomyopathies is very high the 
pediatric heart patient population6. We exploited 
the information obtainable from a pedigree to in-
vestigate the genetic cause of familial HCM in a 
set of triplets (two HCM subjects and one PDA 
case) using a 181-gene targeted NGS approach to 
identify potential pathogenic mutations and genes 
responsible for inherited HCM.
The triplets were born of non-consanguineous 
Saudi parents and were born preterm. Subject 1 
was diagnosed clinically with severe heart failure 
and an HCM phenotype; subject 2 was diagnosed 
with PDA and developed diabetic ketoacidosis at 
age 3; and subject 3 was diagnosed clinically with 
a mild HCM phenotype. Their mother and father 
did not have a clinically relevant history, but there 
was a family history of sudden cardiac death on the 
mother’s side; two cousins died at age 20 and 27 
years from HCM. The family pedigree was high-
ly suggestive of a recessive pattern of inheritance. 
Bioinformatics analysis detected a homozygous 
missense mutation in exon 1 of TMP1 in all trip-
lets that substituted glycine for arginine at codon 3 
(p.Gly3Arg). The variant was heterozygous in the 
parental samples, and there were no disease-caus-
ing mutations in the other 180 genes tested.
TPM1 mutations account for ~3% of cases 
of HCM33-36. TPM1 is essential for normal heart 
development and contractile function37. The sar-
comeric TPM1 gene is considered one of com-
monest causes of HCM 33, DCM38, left ventricular 
noncompaction39, and congenital heart defects 
(CHDs)37.
TPM1 p.Gly3Arg was first reported in Clin-
Var (RCV000036633.3) but the pathogenicity of 
this variant has not been clinically demonstrated. 
The mutation was in a highly conserved region of 
Table III. The predicted ADME properties of the identified compounds using QikProp.
Compound ID Mol  QPlogKp QPlogS Qplog QPlogBB QPPCaco Percentage ROF
 weight    HERG   of HOA
 (Da)       
F0760-0534 352.3 -2.149 -6.424 -6.044 -0.856 652.512 100 0
F1691-3363 368.3 -5.155 -4.169 -4.052 -2.434 45.728 50.106 0
F2258-0953 496.4 -1.629 -6.010 -5.705 -1.022 400.964 100 0
F1278-0497 344.4 -4.700 -5.097 -4.429 -0.877 87.911 67.064 0
F1899-0458 408.4 -2.089 -6.262 -7.220 -1.389 483.378 96.643 0
Table II. Molecular docking results for the identified top hit leads with mutated TPM1.
Compound ID Glide  Glide ΔG bind Interacting
 gscore  energy energy residues
 (kcal/mol)  (kcal/mol) (kcal/mol)  
F0760-0534 -5.354 -33.900 -51.48 Arg27, Ser209
F1691-3363 -5.074 -42.391 -39.91 Arg202, Ser216
F2258-0953 -4.443 -36.600 -39.87 Arg27, Arg202
F1278-0497 -4.379 -31.248 -47.26 Arg27
F1899-0458 -3.471 -40.960 -56.52 Arg27, Arg202, Phe205
PubChem_CID-6918483 -3.300 -21.956 -32.18 Gln20
PubChem_CID-16741 -2.372 -18.128 -27.94 -
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the gene. In silico predictions of the variant were 
“probably damaging” by PolyPhen-2, “damag-
ing” by MetaLR, “damaging” by SIFT (low con-
fidence), “disease causing” by MutationTaster2, 
and “pathogenic” by REVEL. Based on the above 
evidence and following ACMG classification 
guidelines40, we classified the TPM1 p.Gly3Arg 
variant as “likely pathogenic”.
Our in silico studies provide new knowledge 
on the structural impact of the p.Gly3Arg mutation 
and drug binding behavior at the active site of the 
mutated protein. The tertiary protein structure of 
TPM1 was predicted and validated using Ramach-
andran plots and molecular dynamics simulations. 
The Procheck result showed that 98.3% of residues 
fell within the most favored regions and confirmed 
that the structure was very reliable for drug devel-
opment. The molecular dynamics simulation study 
revealed strong structural stability. The predicted 
model was used to perform structure-based virtual 
drug screening to identify potential TPM1 inhib-
itors. Several potent compounds were identified 
that had comparable predicted efficacy and high 
binding affinity, with performance characteris-
tics better than standard drugs. Docking studies 
revealed that Arg27, Gln20, Ser209, and Arg202 
were responsible for the high binding affinity of 
the identified compounds. The RMSD and RMSF 
plot support the evidence observed from docking 
studies, with residue fluctuation and structural 
deviation contributing to the variation in docking 
scores and interactions of the wildtype and mutant 
structures. The binding poses and conformational 
changes varied only slightly between wildtype and 
mutant structures. Furthermore, the pharmaco-
kinetic properties of the identified screened com-
pounds were within acceptable ranges.
Our results predict that the homozygous mis-
sense mutation in exon 1 of TPM1 (p.Gly3Arg) is 
pathogenic could lead to autosomal recessive pedi-
atric HCM and sudden death. Our data support the 
use of the targeted NGS to identify the mutation(s) 
and novel gene(s) responsible for familial DCM of 
unknown genetic cause. Drug binding properties 
play a major role in determining the potency and 
affinity of the drug molecule to the target protein 
active site. The wildtype and mutant structures had 
some differences in their structural conformation 
and binding poses, but this did not significantly 
affect the binding properties of our new candidate 
drugs41,42. Thus, our findings have clear implica-
tions for disease diagnosis and management and 
may be useful in the future for pharmacogenomics 
and personalized medicine approaches in HCM.
Conclusions
TPM1 mutations are a frequent cause of 
HCM, DCM, and congenital heart defects. To 
date, TPM1 has not been associated with isolated 
PDA; here we describe the first case of this asso-
ciation. By predicting a reliable tertiary structure, 
we identified potential TPM1 inhibitors through 
structure-based virtual screening and that had 
acceptable drug-like properties and pharmacoki-
netic profiles. To our knowledge, this is the first 
report of the homozygous missense variation 
p.Gly3Arg in TPM1 in association with a famil-
ial autosomal recessive pediatric HCM and PDA 
phenotype. Our findings suggest that TPM1 p.Gl-
y3Arg is associated with life-threatening, reces-
sively inherited pediatric HCM and PDA, and 
further in vitro and in vivo investigations of the 
identified compounds are warranted.
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